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The traditional Chinese medicine You-Gui-Wan (YGW) contains ten species of medicinal plants and has been used to improve
health in remissive states of asthma for hundreds of years in Asia. However, little is known about the immunomodulatory
mechanisms in vivo. Therefore, this study investigated the pathologic and immunologic responses to YGW in mice that had been
repeatedly exposed to Dermatogoides-pteronyssinus (Der p). YGW reduced Der-p-induced airway hyperresponsiveness and total
IgE in serum. It also inhibited eosinophil inﬁltration by downregulating the protein expression of IL-5 in serum and changed the
Th2-bios in BALF by upregulating IL-12. Results of the collagen assay and histopathologic examination showed that YGW reduced
airway remodeling in the lung. In addition, after YGW treatment there was a relative decrease in mRNA expression of TGF-β1,
IL-13, eotaxin, RANTES, and MCP-1 in lung in the YGW group. The results of EMSA and immunohistochemistry revealed that
YGW inhibited NF-κB expression in epithelial lung cells. YGW exerts its regulative eﬀects in chronic allergic asthmatic mice via its
anti-inﬂammatory activity and by inhibiting the progression of airway remodeling.
1.Introduction
Asthma is a public health problem worldwide, but par-
ticularly in developed countries [1, 2]. Allergic asthma
is deﬁned as an acute-on-chronic inﬂammatory disease
of the airway with characteristic eosinophilic recruitment,
airway hyperresponsiveness (AHR), hyperplasia of goblet
cells, mucus hypersecretion, deposition of collagen, smooth
muscle cell hypertrophy, and subepithelial ﬁbrosis [3, 4]T -
c e l ls u b s e t ss u c ha sT H1, TH2, TH17, and TH9 cells as well as
regulatory T cells regulate immune responses to allergens in
the allergic lung. Moreover, asthma is considered a T helper
2( T H2)-cell-driven inﬂammatory disease [5, 6]. Therefore,
drugs that can suppress TH2 cytokine production would
prove useful as allergen immunotherapy agents [7].
Although corticosteroids and β-agonists can improve
asthma symptoms, they do not cure the disease [8]. These
agents also have side eﬀects, particularly in children. Many
drugs used in Traditional Chinese Medicine (TCM) have
been used for centuries to treat asthma and are still
widely used in modern medical practice in Asian countries.
Recently, many studies have provided evidence of the
therapeutic mechanism of numerous herbal formulas that
are useful for treating allergic asthma [9].
YGW, a standard yang-tonic decoction, has been used
clinically by practitioners of TCM for more than 400 years.
Many clinical observations indicate that YGW is capable
of enhancing the body’s immune system to defend against
pathogens [10]. Moreover, some of the herbs in YGW have
been demonstrated to promote blood circulation and to
have cardioprotective eﬀects [11]. In addition, YGW has
been traditionally used to regulate remissive states of asthma.
However, the mechanisms governing the modulatory eﬀects
of YGW in asthma are not known.
A great deal of information on allergic airway inﬂam-
mation comes from murine model systems using artiﬁcial2 Evidence-Based Complementary and Alternative Medicine
Table 1: Components of herbal medicines in YGW.
TCM materia medica Pharmacognostic nomenclature Amount (g) Part used
(1) Shou Di Huang Rehmanniae glutinosa 8.0 root
(2) Shan Yao Dioscorea opposita 4.0 root
(3) Shan Zhu Yu Cornus oﬃcinalis 4.0 fruit
(4) Gou Qi Zi Lycium chinensis 4.0 fruit
(5) Yu Si Zi Cuscuta chinensis 4.0 seed
(6) Lu Jiao Jiao Cervus elaphus Linnaeus 3.0 horn
(7) Du Zhong Eucommia ulmoides 4.0 cortex
(8) Dang Gui Angelica sinensis 3.0 root
(9) Rou Gui Cinnamomun cassia 2.0 cortex
(10) Fu Zi Aconitum Carmichaeli 2.0 root
Total amounts 38.0
ovalbumin (OVA) combined with adjuvants [5]. However,
OVA is not a major allergen in human asthma. Up to 85%
of patients with allergic asthma are sensitized to house dust
mite (HDMs) allergens, such as Dermatogoides-pteronyssinus
(Der p) [12]. More than ten allergens are found in mites
themselvesandtheirfecalpellets[13–18].Theseallergensare
classiﬁed into diverse protein families with various biological
functions [19, 20]. For instance, Group 1 allergens are
cysteine proteases that cleave intercellular epithelial tight
junctions, permitting the transmission of allergens to the
submucosalofantigen-presentingcells.Group2allergensare
interaction with the innate immune system [21]. Repeated
dust mite allergen exposure can activate TH2a n dT H1, which
together orchestrate subsequent allergic responses resulting
in pulmonary inﬂammation characteristic of chronic allergic
inﬂammation [22].
We developed a mouse model of allergic asthma by
repeatedly exposing BALB/c mice to Der p via intratracheal
exposure to assess the pattern of airway remodeling and the
alteration of inﬂammatory cells and cytokines in BALF after
treatment with YGW. Finally, this study was to determine
the immunomodulatory eﬀect of YGW and understand the
mechanisms by which YGW modulates TH1-TH2 responses
at the molecular level. Mice that are chronically exposed to
Der p exhibit several symptoms that are similar to those
found in patients with allergic asthma, including high levels
ofimmunoglobulin E(IgE)in serum,increasedAHR,airway
inﬂammation, and remodeling [22].
2.MaterialsandMethods
2.1. Mice and Reagents. Animal experiments were carried
out in agreement with the principles outlined by the
Institutional Animal Care and Use Committee of the China
Medical University (number 97-93-N). Speciﬁc pathogen-
free, male, 6-to 8-wk-old BALB/c mice were purchased from
the National Laboratory Animal Center, Republic of China.
The mice were housed in a microisolator cage (Laboratory
Products, Inc., Maywood, NJ, USA) and were fed sterile
food and water ad libitum. Animal care and all experimental
treatments followed the guidelines set-up by the National
Science Council of the Republic of China. Lyophilized Der
p was used in this study (Allergon, Sweden). The crude
Der p preparation was extracted with ether and dialysis
with deionized water. The extracts were lyophilized and
stored at −80◦C before use. LPS concentration in the Der p
preparation was <0.96EU/mg of Der p (Limulus amebocyte
lysate test; E-Toxate; Sigma-Aldrich).
2.2. YGW Preparation. YGW (batch number 98041022) was
supplied by Koda Pharmaceutics Ltd (Taoyuan, Taiwan).
This preparation was a mixture of ten common Chinese
herbal medicines as indicated in Table 1. In brief, these
were extracted with 17.5L and 12.5L of boiled water for
1 hour, respectively. Poaching liquid was mixed two times.
After ﬁltering the liquid, the dregs of the decoction were
removed.Theﬁlteredliquidwaslyophilizedandcrushedinto
a thin powder. The yield of dried extract from starting crude
materialwasestimatedtobe36.31(w/w).YGWwasdissolved
in distilled water and stored at −20◦C before administration
to mice.
2.3. HPLC Analysis of Standard Materials in Test Samples.
YGW (1.00g) was accurately weighed and dissolved in
10mL of methanol. After sonication for 60min at room
temperature, the solution was ﬁltered through the 0.45μm
membrane ﬁlter. YGW was then analyzed by HPLC with
Loganin and Cinnamic acid as standards. HPLC analyses
were conducted with a system consisting of a Hitachi D-7000
Interface, an L-7100 pump, an L-7420 UV/VIS Detector,
an L-7200 Autosampler, and a Mightysil RP-18 (GP) 250
× 4.6mm (5μm) column. The mobile phase containing
Acetonitrile and 0.03% H3PO4 (10:90) was pumped at
a ﬂow rate of 1.0mL/min and the product (eluant) was
detected at 254nm. A typical HPLC chromatogram is shown
in Figure 1(a).T h eR2 values from the calibration curve
of two standards were 1.0000 and 0.9999. The quantity
of standard materials in YGW was calculated as follows:
the amount (mg/g) of standard materials = measured
standard materials (mg/μL) × the HPLC injection volumeEvidence-Based Complementary and Alternative Medicine 3
0
0 1 02 03 04 05 06 07 0
0.05
0.1
0.15
0.2
Retention time (min)
A
b
s
o
r
b
a
n
c
e
 
(
a
.
u
.
)
1
8
.
6
4
,
 
l
o
g
a
n
i
n
3
9
.
4
7
,
 
c
i
n
n
a
m
i
c
 
a
c
i
d
(a)
Oriental medicines
Shan Zhu Yu
Rou Gui
Loganin
Standard materials Content (mg/g)
Cinnamic acid
0.3801
0.0242
(b)
Figure 1: (a) The HPLC chromatogram of YGW. (b) Contents of standard materials in YGW (unit: mg/YGW ex. 1g).
(μL) of YGW × dilution factor/the amount (g) of YGW.
The amounts of standard materials in YGW are given in
Figure 1(b).
2.4. Allergen Challenge and Assessment of Airway Inﬂam-
mation. In the Der p group of BALA/c mice (n = 6),
allergic airway inﬂammation and remodeling were provoked
by subjecting mice to intratracheally administered Der p
(1mg/mL, 50μL) in phosphate-buﬀered saline (PBS) once
a week for 4 weeks (total 5 doses). In the YGW group,
mice were orally administered YGW (1g/kg) 30min before
exposure to Der p. In parallel experiments, na¨ ıve mice were
orally administered water and intratracheally administered
PBS.
Mice were sacriﬁced by i.p. injection of xylazine
(200μg/mice) and ketamine (2mg/mice) three days after
the last challenge as reported previously [23]. Serum and
BALFsampleswerecollectedandstoredat −80◦Cuntilassay.
Diﬀerential counts were performed on cytospin preparations
(1 × 105 cells/100μL of BALF) stained with Liu stain
(Biotech, Taiwan) in a blind manner after total leukocyte
counting.
2.5. Measurement of Airway Hyperresponsiveness. We used
Methacholine-induced pause (Penh) values in live mice as
a marker of airway responsiveness to bronchoconstrictors.
Airway responsiveness was measured in mice using a single-
chamber, whole-body plethysmograph (Buxco Electronics,
Inc., Troy, NY) according to the manufacture’s protocol.
The enhanced pause (Penh) variable was used to estimate
airway resistance. Mice were serially exposed to increasing
doses of nebulized methacholine (0, 3.125, 6.25, 12.5, 25,
and 50mg/mL) (Sigma-Aldrich, St. Louis, MO) in PBS for
3 minutes, respectively, and Penh values were measured for 3
minutes following the end nebulization of methacholine.
2.6. Flow Cytometric Analysis. Monoclonal antibodies used
for ﬂuorescence-activated cell-scan (FACScan) staining
included PE and/or FITC-conjugated anti-mouse CD4
(BD Pharmingen), FITC-conjugated anti-mouse CD8 (BD
Pharmingen), Percp-conjugated anti-mouse CD3 (BD
Pharmingen), and FITC-conjugated anti-mouse CD25.
BALF cells (1 × 105) were stained with mAb for 30min on
ice. After washing, stained cells were quantiﬁed by FACScan
(Becton-Dickinson Immunocytometry system, San Jose,
CA, USA).
2.7. Measurement of Total IgE. Serum samples of total IgE
(1:2 dilution) were measured by ELISA. Brieﬂy, 96-well
plates were coated with puriﬁed anti-mouse IgE (2μg/mL,
R35-72;BDPharmingen).Afterincubationovernightat4◦C,
the plates were washed and then exposed to serum samples
in duplicate for 2h. After washing, biotin anti-mouse IgE
Ab (2μg/mL; BD Pharmingen) was added to individual
wells and allowed to incubate for 1h, followed by washings
and the addition of streptavidin-HRP conjugate (1:1000
dilution, BD Pharmingen). The plates were washed and
developed with a TMB microwell peroxidase substrate sys-
tem (Kirkegaard & Perry Laboratories, Gaithersburg, MD)
a n dr e a da tO D 450. Total IgE concentrations were calculated
by comparison with commercial mouse IgE standards.
2.8. ELISA of Cytokine Levels. IL-4, IL-5, IL-6, IL-12, and
TNF-α levels were measured with an ELISA Ready-SET-
Go! Kit (eBioscience, San Diego, CA), and IL-13, IFN-γ,
and TGF-β levels were measured with an ELISA DuoSet!
Kit (R&D System, Abingdon, UK) according to the man-
ufacturers’s protocols. Standards were run in parallel with
recombinant cytokines.
2.9. Histology and Immunohistochemistry of Lung Specimens.
Paraﬃn-embedded tissue was cut into 5 μms e c t i o n sa n d
stained with H&E and periodic acid-Schiﬀ (PAS) stain. Light
microscopywasusedforhistologicassessment.Thedegreeof
inﬂammatory changes was evaluated with a semiquantitative
scale of 0–5 for inﬂammatory cell inﬁltration, perivascular
spaces, and peribronchial spaces. The scale was graded as
follows: 0 (none), 1 (minimal, <1%), 2 (slight, 1–25%), 3
(moderate, 26–50%), 4 (moderate/severe, 51–75%), and 5
(severe/high, 76–100%). Meanwhile, change in goblet-cell4 Evidence-Based Complementary and Alternative Medicine
Table 2: The total cell number and cellular distributions in BALF of mice 72h after repetitive Der p challenge.
Total cells (×104/mL) Macrophages (%) Lymphocytes (%) Neutrophiles (%) Eosinophiles (%)
Na¨ ıve 13.6 ±2.19 12.60 ±1.91
(92.8 ±3.27%)
0.52 ±0.21
(4.2 ±1.79%)
0.48 ±0.37
(3.4 ± 2.51%)
0
(0%)
Der p 69.0 ±12.25∗ 52.99 ±9.25∗
(77.0 ±4.69%)
4.49 ±1.26∗
(6.6 ±1.81%)
6.81 ±5.05∗
(9.4 ± 6.43%)
4.68 ±1.50∗
(7.0 ±2.55%)
YGW 39.2 ±3.11# 33.17 ±4.00#
(84.6 ±7.23%)
2.99 ±1.53
(7.6 ±3.78%)
2.59 ±1.20
(6.6 ± 3.21%)
0.52 ±0.56#
(1.4 ±1.52%)
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Figure 2: The eﬀects of YGW on antiairway hyperresponsiveness and downregulation of total IgE in a chronic asthmatic mouse model. (a)
Airway hyperresponsiveness was determined two days after the last challenge. (b) YGW signiﬁcantly inhibited the overexpression of IgE in
serum. Values represent the mean ± SD of 6 mice. ∗P<0.05 (versus na¨ ıve group); #P<0.05 (between nontreated and YGW-treated groups).
metaplasia was assessed for muciﬁcation and the presence
of goblet cells in bronchioles as reported previously [24].
The two scores were summed up for individual lesion in
each animal. In the immunohistochemical analysis, the Abs
against the RelA subunit of NF-κB (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) was used as the primary
antibody and HRP-conjugated goat anti-rabbit polycolonal
IgG (ZYMED, San Francisco) was used as the secondary
antibody.Identiﬁcationoftissuesiteswasdeterminedat100x
and 400x magniﬁcation.
2.10. Collagen Analysis. Lung tissue (100mg) from each
group was homogenized mechanically in liquid nitrogen and
then extracted in 2mL HBSS. The supernatant collagen was
quantiﬁed with a Sircol collagen assay kit (Biocolor, Belfast,
UK).
2.11. Reverse Transcription and Quantitative PCR. Total
RNA was extracted from right lung tissue using Trizol
reagent following the manufacturer’s protocol (Invitrogen
Life Technologies). Total RNA was quantiﬁed using a spec-
trophotometer at 260nm. Total RNA samples (1μg/mL)
were reverse-transcribed with an ImProm-II Reverse Tran-
scription System kit (Promega). Quantitative PCR was
carried out with the FastStart Universal SYBR Green Master
kit (Roche). β-actin was used as a control. The primers
(sense and antisense) for each gene were synthesized
as follows: β-actin, 5 -GGAAATCGTG CGTGACA-3  and
5 -CACAGGATTCCATACCCAAG-3 ;T G F - β,5  -GAGCAA-
CATGTGGAACTCTAC-3  and 5 -GCAGTGAGCGCT-
GAATC-3 ; IL-13, 5 -TTATGGTTGTGTGTTATTTAA-
ATGAGTCT-3  and 5 -TGGAGGCTACAGTGAGGT-3 ;
RANTES, 5 -AGAAGTGGGTTCAAGAATACAT-3  and 5 -
GGACCGAGTGGGAGTAG-3 ; Eotaxin, 5 -ACATGTTAC-
ATTTAAGAAATTGGAGTT-3  and5 -AGGTCAGCCTGG-
TCTAC-3 ;a n dM C P - 1 ,5  -AGAAGGAATGGGTCCAGA-
CATA-3  and 5 -TTAAGGCATCACAGTCCGAG-3 .
2.12. Nuclear Extracts and EMSA. Nuclear extracts were
prepared from left lung tissue according to the manu-
facturer’s instructions (Panomics, Redwood). A LightShift
Chemiluminescent EMSA Kit (PIERCE, Rockford) was used
to detect NF-κB expression according to the manufacturer’s
instructions.
2.13. Statistical Analysis. Data are presented as means ± SD.
Diﬀerences between mean values were estimated using a
Student’s t-test. A P value < 0.05 was considered signiﬁcant.
For comparisons of data that were not normally distributed,
a Mann-Whitney U-test was performed.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: The eﬀects of YGW on Der-p-induced airway inﬂammation, goblet cell hyperplasia, mucus hypersecretion, and collagen
deposition in lung tissue of mice. Airway hyperresponsiveness was determined three days after the last challenge. Histopathologic studies
of inﬂammatory cells around the blood vessels (H&E stain; original magniﬁcation, ×400) (a) and activity of goblet cells (PAS; original
magniﬁcation, ×400) in airway epithelial cells (b). Degrees of airway inﬂammation and goblet cell hyperplasia were estimated as described
in Section 2. (c) Collagen levels in lung tissue were signiﬁcantly higher in the Der p group. Values represent the means ± SD of 6 mice.
∗P<0.05 (versus na¨ ıve group); #P<0.05 (between nontreated and YGW-treated groups). Values represent the means ± SD of 6 mice.
3. Results
3.1. Eﬀects of YGW on Antiairway Inﬂammation, Antiairway
Hyperresponsiveness, and Downregulation of Total IgE in a
Chronic Asthmatic Mouse Model. We used a repetitive Der p
challenge experiment to test the eﬀects of YGW on allergen-
induced chronic airway inﬂammation in a mouse model.
Table 2 showsthetotalanddiﬀerentcellcountsinBALFfrom
mice that had been treated with or without YGW during
repeated Der p intratracheal inoculation periods (at 1-week
intervals). In na¨ ıve mice, the cells in BALF were mostly
macrophages, and no eosinophils were detected. However, in
the Der p group, the numbers of total cells, macrophages,
and eosinophils in BALF were markedly higher than those
in na¨ ıve mice. Numbers of total cells, macrophages and
eosinophils in BALF after allergen challenge were signif-
icantly lower in mice in the YGW group than these in
untreated challenged mice.
We determined the correlation between airway inﬂam-
mation and airway AHR. Mice in the Der p group had higher
Penhvaluesthanthoseinthena¨ ıvegroup.IntheYGWgroup,
there was a marked decrease in Penh values at maximal dose
of methacholine (50mg/mL) relative to the Der p group
(Figure 2(a)).6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The eﬀe c to fY G Wo nT - c e l ls u b s e t si nB A L Fo fc h a l l e n g e dm i c e .( a )C D 3 +/CD4+,( b )C D 3 +/CD8+,a n d( c )C D 4 +/CD25+
lymphocyte levels were determined by ﬂow cytometry with immunoﬂuorescence of monoclonal antibodies. Data are representative of the
results from three separate experiments. ∗P<0.05 (versus na¨ ıve group); #P<0.05 (between nontreated and YGW-treated groups).
To determine the eﬀects of YGW treatment on humoral
immune responses, we measured serum total IgE. A signif-
icant increase in the levels of serum total IgE was observed
in the Der p group relative to the na¨ ıve group (Figure 2(b)).
After treatments with YGW in the sensitization period, the
serum concentrations of total IgE decreased signiﬁcantly.
3.2. YGW Attenuates Der-p-Induced Lung Pathology. The
characteristic features of asthmatic airway are cell inﬂam-
mation, the presence of hyperplastic goblet cells, mucus
secretion, and collagen deposition. The left lungs of mice
were histologically examined 72h after the ﬁnal antigen
challenge. Histological sections of lung tissue from Der p-
challenged mice exhibited increased airway inﬂammation,
matrix deposition in subepithelial regions, and excessive
mucus secretion from hyperplastic goblet cells (Figure 3),
relative to mice in the na¨ ıve group. In contrast, mice that
had been treated with YGW showed signiﬁcantly less airway
inﬂammation, fewer PAS-positive cells, and less collagen
deposition than mice in the Der p group.
3.3.TheEﬀectofYGWonT-CellSubsetsinBALFofChallenged
Mice. The eﬀect of YGW on the percentage change of T-cell
subsets was determined by ﬂow cytometry with immunoﬂu-
orescence of monoclonal antibodies to CD3+,C D 4 +,C D 8 +,
and CD25+,r e s p e c t i v e l y( Figure 4). There was a signiﬁcant
increase in the percentage of CD3+/CD4+ and numbers of
CD4+/CD25+ lymphocytes in Der p group mice relative to
the na¨ ıve group. YGW group mice showed a signiﬁcantly
lower percentage of CD3+/CD4+ and CD4+/CD25+ lympho-
cytes than Der p mice. However, there was no signiﬁcant
diﬀerence in CD3+/CD8+ lymphocyte levels in BALF among
the three groups of mice.
3.4.YGWAttenuatesCytokineProductioninBALFandSerum.
To determine the possible eﬀect of YGW on T-cell responses,
we evaluated the eﬀects of YGW on T-cell cytokine secretion
in BALF and serum. The production of IL-4, IL-5, IL-12,
IL-13, TNF-α,T G F - β,a n dI F N - γ was analyzed by ELISA
(Figure 5). YGW signiﬁcantly attenuated the expression of
Der-p-induced IL-13, TNF-α,a n dT G F - β in BALF but
resultedinanincreaseinIL-12productionrelativetomicein
the Der p group. YGW group mice also showed signiﬁcantly
lower levels of IL-5 in serum, but not in BALF, than mice in
the Der p group. Similarly, there were no changes in IL-4 or
INF-γ levels among the YGW groups of mice.
3.5. Immunoregulation of YGW on Der-p-Induced Proinﬂam-
matory Cytokine and Chemokine Gene Expression in Lung
Tissues. After Der p allergen challenge, the expression levelsEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: The expression levels of IL-13, TGF-β,a n dT N F - α in BALF were reduced by YGW, but levels of IL-12 increased. YGW resulted in
reduced production of IL-5 cytokine in serum. ∗P<0.05 (versus na¨ ıve group); #P<0.05 (between nontreated and YGW-treated groups).8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Real-time PCR analysis indicated that YGW exerts its suppressive eﬀects by regulating the expression of TH2-related genes and
chemokines in lung tissue. This real-time PCR proﬁle was representative of three independent experiments.
of IL-13, Eotaxin, RANTES, MCP-1, and TGF-β mRNA
in lung tissues from the Der p group were higher than
those in the na¨ ıve group (Figure 6). Lung tissue from mice
pretreated with YGW showed signiﬁcantly lower levels of IL-
13, Eotaxin, RANTES, MCP-1, and TGF-β synthesis than
lung tissues from mice in the Der p group.
3.6. NF-κBA c t i v a t i o nW a sS u p p r e s s e di nD e r - p - T r e a t e dL u n g
Tissues by YGW. To test whether the inhibitory eﬀect of
YGW on Der-p-challenged animals leads to NF-κBa c t i v a -
tion, the eﬀects of YGW on expression of NF-κB were exam-
ined by immunohistochemistry and its eﬀects on NF-κB-
speciﬁc DNA-protein binding activity were examined using
EMSA. Immunohistochemistry staining showed that YGW
inhibited the expression of NF-κB in bronchiolar epithelial
cells of Der-p-challenged mice (Figure 7(a)). EMSA revealed
that YGW inhibited NF-κB-speciﬁc DNA-protein binding
activity in lung tissues (Figure 7(b)).
4. Discussion
In this study, we provide evidence for the immunoregulatory
eﬀects of YGW on allergen-induced airway inﬂammation
and airway hypersensitivity in an established murine model
of chronic allergic asthma.
We demonstrated that oral administration of YGW sup-
pressedAHRandreducedthedegreeofairwayinﬂammation
and remodeling. YGW possesses anti-inﬂammatory eﬀectsEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: (a) In the immnuohistochemistry assay, YGW inhibited the expression of NF-κB( R e lA ;×400) in bronchiolar epithelial cells of
mice after repetitive Der p challenge. (b) EMSA showed that YGW decreased NF-κB activation in whole lung tissue after Der p stimulation.
The arrow indicates the speciﬁc DNA-probe complex. Data are representative of results from three separate experiments.
as evidenced by the reduction in total numbers of cells
and the percent of macrophages and eosinophils in BALF
relative to those seen in Der p group mice. Moreover, YGW
also reduced inﬂammation and the number of hyperplastic
g o b l e tc e l l sa se v i d e n c e db yl u n gh i s t o l o g ya n a l y s i sa sw e l la s
attenuated deposition of collagen. Therefore, YGW appears
to suppress AHR by protecting against airway inﬂammation,
eosinophilia inﬁltration, and airway remodeling.
It is well established that elevated levels of serum
IgE correlate with the incidence or severity of asthma.
Therefore, interfering with synthesis of IgE or inhibiting its
action has recently become a novel therapeutic approach
for development of immunological drugs in asthma, such
as omalizumab (Xolair) [3]. In the present study, YGW
treatment signiﬁcantly decreased total IgE in serum. Fur-
thermore, we also found that YGW treatment resulted in a
reduction in IgG1 levels and in slight elevation of IgG2a/2b
levels (data not show).
T cells with a TH2-like phenotype are thought to play an
important role in orchestrating the asthmatic inﬂammatory
response [25]. Therefore, the immunomodulatory role of
YGW in allergen-sensitized mice may lie in its ability to reg-
ulate T-cell activation. In this study, ﬂow cytometry analysis
showed that YGW led to a decrease in the percentage of the
CD3+CD4+ T-cell subset in BALF, but not the CD3+CD8+
T-cell subset. On the other hand, CD25+CD4+ regulatory T
cells suppress immune responses and are believed to play
roles in preventing autoimmune diseases [26]. It has been
reported that regulatory T cells downregulate CD25−CD4+
T-cell-mediated production of IL-12 in antigen-presenting
cells [27]. In our study, we found that YGW reduced the
number of CD4+CD25+ T cells in BALF, suggesting that
YGW may block this feedback system and shift Th2-bios by
increasing IL-12 levels. Further studies are needed to verify
the eﬀect of YGW on changing T-cell subsets during allergic
inﬂammation.
Blood and tissue eosinophilia are hallmarks of allergic
rhinitis, atopic dermatitis, and atopic asthma. Eosinophils
are recruited from the circulation to inﬂammatory tissues
in response to allergic stimuli [28]. Moreover, eosinophils10 Evidence-Based Complementary and Alternative Medicine
contribute to the symptomatology of asthma by releasing
granule-storedcationicproteinsandproinﬂammatorymedi-
ators, including cytokines and chemokines [29]. Therefore,
the eosinophil is thought to be a key eﬀector cell in the
pathogenesis of allergic disease [29]. Notably, the important
regulators of eosinophil traﬃcking are TH2 cytokines such
as IL-4, IL-5, and IL-13 [29, 30], although chemokines,
eotaxis, and RANTES are also involved in recruitment of
eosinophils [31]. In addition, only IL-5 is speciﬁc for termi-
nal diﬀerentiation, growth, and survival of eosinophils [32,
33]. Thus, suppression of these cytokines and chemokines
may be eﬀective in reducing eosinophil inﬁltration into
lung, thereby alleviating allergic asthmatic inﬂammation.
In addition, RANTES and MCP-1 are also involved in
recruitment of monocytes [34]. In our present student we
showed that YGW treatment decreased the secretion of IL-
5 in serum and IL-13 in lung tissue but did not aﬀect IL-4
levels in serum. Meanwhile, YGW treatment downregulated
mRNA expression of IL-13, eotaxin, RANTES, and MCP-1
in lung tissue. Therefore, we speculate that YGW treatment
reduces eosinophil inﬁltration into lung by modulating TH2
responses at the molecular level.
In asthmatics, one important feature of airway remod-
eling is subepithelial ﬁbrosis [35]. TGF-β is a proﬁbrogenic
growth factor, which stimulates the diﬀerentiation of ﬁbrob-
last precursors to myoﬁbroblast cells, which in turn induces
their proliferation [36]. Moreover, it has been shown to
elicit the expression of MMPs and TIMPs [37]. Meanwhile,
many studies have shown that TGF-β and eosinophils play
important roles in the development of airway remodeling
[38–41].
The rate of apoptosis of bronchial epithelial cells is
signiﬁcantly higher in asthma patients than that in healthy
people, and TNF-α is suggested to play a crucial role in
this process [42, 43]. In addition, TNF-α can regulate
overproduction of ECM proteins by inducing epithelial cells,
ﬁbroblasts, and ASM cells [44]. Simultaneously, TNF-α and
IL-1β can induce the synthesis of eotaxin [45] and RANTES
[46] in human lung epithelial cells.
W ef o u n dt h a tY G Wt r e a t m e n tr e s u l t e di nd e c r e a s e d
secretion of TGF-β and TNF-α in BALF and the down-
regulation of mRNA expression of TGF-β in lung tissues.
Therefore, we propose that YGW treatment reduces airway
subepithelial ﬁbrosis by downregulating the expression of
TGF-β and TNF-α.
NF-κB is capable of regulating TH2c e l ld i ﬀerentiation
and producing proinﬂammatory mediators that are required
for induction of allergic airway inﬂammation [47]. Bureau
et al. [48] reported that bronchial epithelial and/or air-
way immune cells displayed augmented NF-κBa c t i v i t yi n
OVA/OVA mice [48]. Therefore, targeting of the NF-κB
signaling pathway may be a promising therapy for asthma
[48]. However, whether the immunoregulatory activity of
YGW against asthma is connected with a diminution of
NF-κB activity in the lung is not clear. To address these
issues, we used immunohistochemistry and EMSA to detect
NF-κB expression and activation in lung of repeatedly Der
p challenge mice. We found that oral administration of
YGW markedly reduced NF-κB expression, predominantly
in bronchial epithelium. EMSA analysis also revealed a
decrease in NF-κBa c t i v a t i o ni nt h ew h o l el u n g( Figure 7).
Taken together, we speculate that inhibition of NF-κBa c t i -
vation directly or indirectly attenuated IL-5, IL-13, eotaxin,
RANTES, TNF-α,a n dT G F - β gene expression, eosinophilia
inﬁltration, mucus production, collagen deposition, and
allergic lung inﬂammation.
In conclusion, YGW-induced attenuation of AHR,
remodeling, and inﬂammation in this model of chronic
asthma is associated with speciﬁc downregulation of TH2
cytokines and inhibition of NF-κB activation within the
bronchial epithelium in lung. To the best of our knowledge,
this is the ﬁrst study to show that YGW has immunoregula-
tion eﬀects in remissive states of asthma. The pharmacologi-
cally active components of YGW, however, have not yet been
characterized. Further research will be required to dissect the
mechanisms of action of this formula.
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